Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Identifieur interne : 003695 ( Main/Exploration ); précédent : 003694; suivant : 003696Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Auteurs : Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Alzheimer Disease (therapy), Antipsychotic, Antipsychotic Agents (therapeutic use), Cholinesterase, Cholinesterase Inhibitors (adverse effects), Cholinesterase Inhibitors (therapeutic use), Counseling, DLB, Humans, Lewy Body Disease (drug therapy), Lewy Body Disease (therapy), Lewy body dementia, Nervous system diseases, PDD, Parkinson Disease (drug therapy), Parkinson Disease (therapy), Parkinson disease, Psychoses, Substance-Induced (drug therapy), Psychoses, Substance-Induced (etiology), Serotonin Uptake Inhibitors (therapeutic use), Treatment, antipsychotics, cholinesterase inhibitor.
- MESH :
- chemical , adverse effects : Cholinesterase Inhibitors.
- chemical , therapeutic use : Antipsychotic Agents, Cholinesterase Inhibitors, Serotonin Uptake Inhibitors.
- drug therapy : Lewy Body Disease, Parkinson Disease, Psychoses, Substance-Induced.
- etiology : Psychoses, Substance-Induced.
- therapy : Alzheimer Disease, Lewy Body Disease, Parkinson Disease.
- Counseling, Humans.
Abstract
Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20544
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001799
- to stream Istex, to step Curation: 001799
- to stream Istex, to step Checkpoint: 002101
- to stream PubMed, to step Corpus: 002F32
- to stream PubMed, to step Curation: 002F32
- to stream PubMed, to step Checkpoint: 002F26
- to stream Ncbi, to step Merge: 001380
- to stream Ncbi, to step Curation: 001380
- to stream Ncbi, to step Checkpoint: 001380
- to stream Main, to step Merge: 004D78
- to stream PascalFrancis, to step Corpus: 001D73
- to stream PascalFrancis, to step Curation: 000F48
- to stream PascalFrancis, to step Checkpoint: 001C81
- to stream Main, to step Merge: 005159
- to stream Main, to step Curation: 003695
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20544</idno><idno type="url">https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001799</idno><idno type="wicri:Area/Istex/Curation">001799</idno><idno type="wicri:Area/Istex/Checkpoint">002101</idno><idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16092095</idno><idno type="wicri:Area/PubMed/Corpus">002F32</idno><idno type="wicri:Area/PubMed/Curation">002F32</idno><idno type="wicri:Area/PubMed/Checkpoint">002F26</idno><idno type="wicri:Area/Ncbi/Merge">001380</idno><idno type="wicri:Area/Ncbi/Curation">001380</idno><idno type="wicri:Area/Ncbi/Checkpoint">001380</idno><idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno><idno type="wicri:Area/Main/Merge">004D78</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0457542</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D73</idno><idno type="wicri:Area/PascalFrancis/Curation">000F48</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C81</idno><idno type="wicri:doubleKey">0885-3185:2005:Poewe W:treatment:of:dementia</idno><idno type="wicri:Area/Main/Merge">005159</idno><idno type="wicri:Area/Main/Curation">003695</idno><idno type="wicri:Area/Main/Exploration">003695</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="4"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Medical University of Innsbruck</wicri:regionArea><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S77">S77</biblScope><biblScope unit="page" to="S82">S82</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno><idno type="DOI">10.1002/mds.20544</idno><idno type="ArticleID">MDS20544</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (therapy)</term><term>Antipsychotic</term><term>Antipsychotic Agents (therapeutic use)</term><term>Cholinesterase</term><term>Cholinesterase Inhibitors (adverse effects)</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Counseling</term><term>DLB</term><term>Humans</term><term>Lewy Body Disease (drug therapy)</term><term>Lewy Body Disease (therapy)</term><term>Lewy body dementia</term><term>Nervous system diseases</term><term>PDD</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Psychoses, Substance-Induced (etiology)</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Treatment</term><term>antipsychotics</term><term>cholinesterase inhibitor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cholinesterase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Cholinesterase Inhibitors</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lewy Body Disease</term><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Alzheimer Disease</term><term>Lewy Body Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Counseling</term><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term><term>Cholinesterase</term><term>Démence corps Lewy</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082
|texte= Treatment of dementia with Lewy bodies and Parkinson's disease dementia
}}
| This area was generated with Dilib version V0.6.23. |  |